Regeneron Pharmaceuticals Inc (REGN)
820.94
-7.93
(-0.96%)
USD |
NASDAQ |
Nov 05, 10:23
Regeneron Pharmaceuticals Free Cash Flow: 3.319B for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
September 30, 2024 | 3.319B |
June 30, 2024 | 3.184B |
March 31, 2024 | 3.930B |
December 31, 2023 | 3.668B |
September 30, 2023 | 4.359B |
June 30, 2023 | 3.004B |
March 31, 2023 | 2.527B |
December 31, 2022 | 3.398B |
September 30, 2022 | 4.148B |
June 30, 2022 | 7.869B |
March 31, 2022 | 7.936B |
December 31, 2021 | 6.529B |
September 30, 2021 | 5.381B |
June 30, 2021 | 1.694B |
March 31, 2021 | 2.029B |
December 31, 2020 | 2.004B |
September 30, 2020 | 1.582B |
June 30, 2020 | 2.425B |
March 31, 2020 | 1.706B |
December 31, 2019 | 2.000B |
September 30, 2019 | 1.995B |
June 30, 2019 | 1.906B |
March 31, 2019 | 2.095B |
December 31, 2018 | 1.812B |
September 30, 2018 | 1.628B |
Date | Value |
---|---|
June 30, 2018 | 1.636B |
March 31, 2018 | 1.268B |
December 31, 2017 | 1.034B |
September 30, 2017 | 815.17M |
June 30, 2017 | 992.46M |
March 31, 2017 | 1.339B |
December 31, 2016 | 974.00M |
September 30, 2016 | 838.08M |
June 30, 2016 | 1.052B |
March 31, 2016 | 809.63M |
December 31, 2015 | 652.85M |
September 30, 2015 | 629.44M |
June 30, 2015 | -32.77M |
March 31, 2015 | 214.84M |
December 31, 2014 | 419.43M |
September 30, 2014 | 551.55M |
June 30, 2014 | 527.76M |
March 31, 2014 | 355.93M |
December 31, 2013 | 432.27M |
September 30, 2013 | 297.54M |
June 30, 2013 | 224.15M |
March 31, 2013 | 39.19M |
December 31, 2012 | -123.95M |
September 30, 2012 | -263.58M |
June 30, 2012 | -306.58M |
Free Cash Flow Range, Past 5 Years
1.582B
Minimum
Sep 2020
7.936B
Maximum
Mar 2022
3.635B
Average
3.252B
Median
Free Cash Flow Benchmarks
Amgen Inc | 6.283B |
Eli Lilly and Co | -2.275B |
Pfizer Inc | 4.81B |
Biogen Inc | 1.768B |
Vertex Pharmaceuticals Inc | -1.426B |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 1.291B |
Cash from Investing (Quarterly) | -574.40M |
Cash from Financing (Quarterly) | -634.00M |
Free Cash Flow Per Share (Quarterly) | 9.030 |
Free Cash Flow to Equity (Quarterly) | 1.049B |
Free Cash Flow to Firm (Quarterly) | 1.049B |
Free Cash Flow Yield | 3.51% |